週边血单核细胞市场－全球产业规模、份额、趋势、机会和预测，按产品、应用、技术、来源、地区和竞争细分，2020 年至 2030 年

2024年全球週边血单核细胞市场价值为2.8089亿美元，预计2030年将达到4.9602亿美元，预测期内复合年增长率为10.02%。全球週边血单核细胞市场正在经历显着增长，这得益于细胞疗法数量的不断增长、毒理学测试研发需求的不断增长以及新产品稳定开发所需的化合物反应机制。例如，2023年6月，美国国家医学图书馆发表的一项研究评估了体外感染克氏锥虫哥伦比亚株（Col）并用苯并硝唑治疗的周边血单核细胞（PBMC）的免疫反应。

关键市场驱动因素

政府资助的细胞疗法和免疫学研究

主要市场挑战

监管和品质合规的复杂性

主要市场趋势

扩大在疫苗开发和免疫监测中的作用

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：COVID-19 对全球週边血单核细胞市场的影响

第五章：顾客之声

第六章：全球週边血单核细胞市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 副产品（冷冻保存或冷冻的 PBMC、培养或新鲜 PBMC 和周边血单核细胞分离和活力试剂盒）
  • 按应用（免疫学、传染病、血液学及其他）
  • 依技术（密度梯度离心法和白血球分离术）
  • 按来源（人类和动物）
  • 按地区（北美、欧洲、亚太、南美、中东和非洲）
  • 按公司分类（2024）
• 市场地图
  • 按产品
  • 按应用
  • 依技术
  • 按来源
  • 按地区

第七章：北美週边血单核细胞市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第八章：欧洲週边血单核细胞市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第九章：亚太週边血单核细胞市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 日本
  • 印度
  • 韩国
  • 澳洲

第十章：南美洲週边血单核细胞市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 11 章：中东和非洲週边血单核细胞市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 阿联酋
  • 沙乌地阿拉伯
  • 南非

第 12 章：市场动态

• 驱动程式
• 挑战

第十三章：市场趋势与发展

• 合併与收购（如有）
• 产品发布（如有）
• 最新动态

第 14 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品/服务的威胁

第 15 章：SWOT 分析：全球週边血单核细胞市场

第 16 章：临床试验分析

第 17 章：竞争格局

• Charles River Laboratories International, Inc.
• Lonza Group AG
• Corning Inc.
• Bio-Rad Laboratories Inc.
• ABCAM
• Biolegend Inc.
• ZEN-Bio Inc.
• DAPCEL, Inc.
• Creative Bioarray
• iXCells Biotechnologies USA, LLC

第 18 章：策略建议

第19章调查会社について・免责事项

Global Peripheral Blood Mononuclear Cells Market was valued at USD 280.89 million in 2024 and is expected to reach USD 496.02 million by 2030 with a CAGR of 10.02% during the forecast period. The global market for Peripheral Blood Mononuclear Cells is experiencing significant growth, driven by the rising rate in number of cell therapies, high demand of research and development for toxicology testing and reaction mechanism of the compound responsible for new and stable development of products. For instance, in June 2023, a study published in National Library of Medicine, it assessed the immune response of peripheral blood mononuclear cells (PBMC) that were infected in vitro with the Colombian strain (Col) of Trypanosoma cruzi and treated with Benzonidazole.

Key Market Drivers

Government-Funded Cell Therapy and Immunology Research

Governments worldwide are significantly increasing investments in cell and gene therapy, where PBMCs play a critical role. In the U.S., the National Institutes of Health (NIH) continues to back programs-such as immuno-oncology and vaccine research-that rely heavily on PBMC-based assays to characterize immune responses before and after experimental treatments. NIH-funded vaccine programs studying T-cell immunity routinely isolate PBMCs from donors to quantify immunogenicity in clinical testing. Similarly, in Europe, the Innovative Medicines Initiative (IMI)-a €2 billion public-private partnership co-funded by the European Commission-supports drug development platforms that use PBMC-based biomarker identification and immune monitoring in early-phase clinical trials. This large-scale public-sector support for PBMC-integrated therapeutics research underlines PBMCs' indispensable role in translational medicine and offers a robust, policy-backed driver for market expansion.

Key Market Challenges

Regulatory and Quality Compliance Complexity

A significant challenge arises from the stringent and fragmented regulatory frameworks governing PBMC collection, processing, and distribution across jurisdictions. In the European Union, PBMC isolation facilities must conform to EU Tissue and Cells Directives (EUTCD) as well as national regulatory agency audits (e.g., Germany's Paul-Ehrlich-Institut), with repeat compliance checks and data privacy enforcement under GDPR-violations can incur fines exceeding €20 million. In China, PBMC processing kits are treated as Class III medical devices requiring clinical validation, and export of PBMC samples with human genetic information is restricted under the 2021 Biosecurity Law, mandating dual approvals from NMPA and the Ministry of Commerce. These variable, complex regulations raise costs for cross-border research and discourage adoption in regions without harmonized oversight, inhibiting global standardization and scalable PBMC usage.

Key Market Trends

Expanding Role in Vaccine Development and Immuno-Monitoring

A rapidly emerging trend is the expanded application of PBMCs for vaccine research and immunogenicity evaluation, especially in government-backed vaccine rollouts and pandemic preparedness. PBMCs offer critical insight into T-cell responses, cytokine profiles, and durability of immune memory. Governments funding large-scale vaccine trials-for diseases like COVID-19, malaria, tuberculosis-routinely incorporate PBMC-based assays into protocols to evaluate safety and immune efficacy. This creates predictable public-sector demand for standardized PBMC isolation, storage, and testing services, accelerating market growth tied to national immunization programs.

Key Market Players

• Charles River Laboratories International, Inc.
• Lonza Group AG
• Corning Inc.
• Bio-Rad Laboratories Inc.
• ABCAM
• Biolegend Inc.
• ZEN-Bio Inc.
• DAPCEL, Inc.
• Creative Bioarray
• iXCells Biotechnologies USA, LLC

Report Scope:

In this report, the Global Peripheral Blood Mononuclear Cells Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Peripheral Blood Mononuclear Cells Market, By Product:

• Cryopreserved or Frozen PBMC
• Cultured or Fresh PBMC
• Peripheral Blood Mononuclear Cell Isolation & Viability Kits

Peripheral Blood Mononuclear Cells Market, By Application:

• Immunology
• Infectious Disease
• Hematology
• Others

Peripheral Blood Mononuclear Cells Market, By Technique:

• Density Gradient Centrifugation Process
• Leukapheresis

Peripheral Blood Mononuclear Cells Market, By Source:

• Human
• Animals

Peripheral Blood Mononuclear Cells Market, By Region:

• North America
  • United States
  • Mexico
  • Canada
• Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain
• Asia-Pacific
  • China
  • India
  • South Korea
  • Japan
  • Australia
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Peripheral Blood Mononuclear Cells Market.

Available Customizations:

Global Peripheral Blood Mononuclear Cells Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Peripheral Blood Mononuclear Cells Market

5. Voice of Customer

6. Global Peripheral Blood Mononuclear Cells Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product (Cryopreserved or Frozen PBMC, Cultured or Fresh PBMC and Peripheral Blood Mononuclear Cell Isolation & Viability Kits)
  • 6.2.2. By Application (Immunology, Infectious Disease, Hematology and Others)
  • 6.2.3. By Technique (Density Gradient Centrifugation Process and Leukapheresis)
  • 6.2.4. By Source (Human and Animals)
  • 6.2.5. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
  • 6.2.6. By Company (2024)
• 6.3. Market Map
  • 6.3.1. By Product
  • 6.3.2. By Application
  • 6.3.3. By Technique
  • 6.3.4. By Source
  • 6.3.5. By Region

7. North America Peripheral Blood Mononuclear Cells Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Application
  • 7.2.3. By Technique
  • 7.2.4. By Source
  • 7.2.5. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Peripheral Blood Mononuclear Cells Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By Technique
      • 7.3.1.2.4. By Source
  • 7.3.2. Canada Peripheral Blood Mononuclear Cells Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By Technique
      • 7.3.2.2.4. By Source
  • 7.3.3. Mexico Peripheral Blood Mononuclear Cells Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By Technique
      • 7.3.3.2.4. By Source

8. Europe Peripheral Blood Mononuclear Cells Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Application
  • 8.2.3. By Technique
  • 8.2.4. By Source
  • 8.2.5. By Country
• 8.3. Europe: Country Analysis
  • 8.3.1. Germany Peripheral Blood Mononuclear Cells Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By Technique
      • 8.3.1.2.4. By Source
  • 8.3.2. France Peripheral Blood Mononuclear Cells Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By Technique
      • 8.3.2.2.4. By Source
  • 8.3.3. United Kingdom Peripheral Blood Mononuclear Cells Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By Technique
      • 8.3.3.2.4. By Source
  • 8.3.4. Italy Peripheral Blood Mononuclear Cells Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By Technique
      • 8.3.4.2.4. By Source
  • 8.3.5. Spain Peripheral Blood Mononuclear Cells Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By Technique
      • 8.3.5.2.4. By Source

9. Asia-Pacific Peripheral Blood Mononuclear Cells Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Application
  • 9.2.3. By Technique
  • 9.2.4. By Source
  • 9.2.5. By Country
• 9.3. Asia-Pacific: Country Analysis
  • 9.3.1. China Peripheral Blood Mononuclear Cells Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By Technique
      • 9.3.1.2.4. By Source
  • 9.3.2. Japan Peripheral Blood Mononuclear Cells Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By Technique
      • 9.3.2.2.4. By Source
  • 9.3.3. India Peripheral Blood Mononuclear Cells Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By Technique
      • 9.3.3.2.4. By Source
  • 9.3.4. South Korea Peripheral Blood Mononuclear Cells Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Product
      • 9.3.4.2.2. By Application
      • 9.3.4.2.3. By Technique
      • 9.3.4.2.4. By Source
  • 9.3.5. Australia Peripheral Blood Mononuclear Cells Market Outlook
    • 9.3.5.1. Market Size & Forecast
      • 9.3.5.1.1. By Value
    • 9.3.5.2. Market Share & Forecast
      • 9.3.5.2.1. By Product
      • 9.3.5.2.2. By Application
      • 9.3.5.2.3. By Technique
      • 9.3.5.2.4. By Source

10. South America Peripheral Blood Mononuclear Cells Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Application
  • 10.2.3. By Technique
  • 10.2.4. By Source
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Peripheral Blood Mononuclear Cells Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By Technique
      • 10.3.1.2.4. By Source
  • 10.3.2. Argentina Peripheral Blood Mononuclear Cells Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By Technique
      • 10.3.2.2.4. By Source
  • 10.3.3. Colombia Peripheral Blood Mononuclear Cells Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By Technique
      • 10.3.3.2.4. By Source

11. Middle East and Africa Peripheral Blood Mononuclear Cells Market Outlook

• 11.1. Market Size & Forecast
  • 11.1.1. By Value
• 11.2. Market Share & Forecast
  • 11.2.1. By Product
  • 11.2.2. By Application
  • 11.2.3. By Technique
  • 11.2.4. By Source
  • 11.2.5. By Country
• 11.3. MEA: Country Analysis
  • 11.3.1. UAE Peripheral Blood Mononuclear Cells Market Outlook
    • 11.3.1.1. Market Size & Forecast
      • 11.3.1.1.1. By Value
    • 11.3.1.2. Market Share & Forecast
      • 11.3.1.2.1. By Product
      • 11.3.1.2.2. By Application
      • 11.3.1.2.3. By Technique
      • 11.3.1.2.4. By Source
  • 11.3.2. Saudi Arabia Peripheral Blood Mononuclear Cells Market Outlook
    • 11.3.2.1. Market Size & Forecast
      • 11.3.2.1.1. By Value
    • 11.3.2.2. Market Share & Forecast
      • 11.3.2.2.1. By Product
      • 11.3.2.2.2. By Application
      • 11.3.2.2.3. By Technique
      • 11.3.2.2.4. By Source
  • 11.3.3. South Africa Peripheral Blood Mononuclear Cells Market Outlook
    • 11.3.3.1. Market Size & Forecast
      • 11.3.3.1.1. By Value
    • 11.3.3.2. Market Share & Forecast
      • 11.3.3.2.1. By Product
      • 11.3.3.2.2. By Application
      • 11.3.3.2.3. By Technique
      • 11.3.3.2.4. By Source

12. Market Dynamics

• 12.1. Drivers
• 12.2. Challenges

13. Market Trends & Developments

• 13.1. Merger & Acquisition (If Any)
• 13.2. Product Launches (If Any)
• 13.3. Recent Developments

14. Porters Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products/Services

15. SWOT Analysis: Global Peripheral Blood Mononuclear Cells Market

16. Clinical Trial Analysis

• 16.1. Ongoing Clinical Trials
• 16.2. Completed Clinical Trials
• 16.3. Terminated Clinical Trials
• 16.4. Breakdown of Pipeline, By Development Phase
• 16.5. Breakdown of Pipeline, By Status
• 16.6. Breakdown of Pipeline, By Study Type
• 16.7. Breakdown of Pipeline, By Region
• 16.8. Clinical Trials Heat Map

17. Competitive Landscape

• 17.1. Charles River Laboratories International, Inc.
  • 17.1.1. Business Overview
  • 17.1.2. Company Snapshot
  • 17.1.3. Products & Services
  • 17.1.4. Financials (As Reported)
  • 17.1.5. Recent Developments
  • 17.1.6. Key Personnel Details
  • 17.1.7. SWOT Analysis
• 17.2. Lonza Group AG
• 17.3. Corning Inc.
• 17.4. Bio-Rad Laboratories Inc.
• 17.5. ABCAM
• 17.6. Biolegend Inc.
• 17.7. ZEN-Bio Inc.
• 17.8. DAPCEL, Inc.
• 17.9. Creative Bioarray
• 17.10. iXCells Biotechnologies USA, LLC

18. Strategic Recommendations

19. About Us & Disclaimer